Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\class-wp-theme.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\class-wp-theme.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\rest-api\endpoints\class-wp-rest-taxonomies-controller.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\rest-api\endpoints\class-wp-rest-taxonomies-controller.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\rest-api\endpoints\class-wp-rest-application-passwords-controller.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\rest-api\endpoints\class-wp-rest-application-passwords-controller.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\block-patterns.php on line 1

Notice: Uninitialized string offset: 0 in C:\webapps\propertymentorgroup\wp-includes\block-patterns.php on line 1
Big Movers: Ericsson (NASDAQ:ERIC), U.S. Bancorp (NYSE:USB), NeuroMetrix Inc. (NASDAQ:NURO), Alcatel Lucent SA (ADR) (NYSE:ALU), Pfizer Inc. (NYSE:PFE) - Property Mentor Group

Big Movers: Ericsson (NASDAQ:ERIC), U.S. Bancorp (NYSE:USB), NeuroMetrix Inc. (NASDAQ:NURO), Alcatel Lucent SA (ADR) (NYSE:ALU), Pfizer Inc. (NYSE:PFE)


On last trading day Ericsson (NASDAQ:ERIC) moved down -0.46% to close at $12.89. Its volatility for the week is 1.42% while volatility for the month is 1.33%. ERIC’s sales growth for past 5 years was 2.00% and its EPS growth for past 5 years was 25.80%. Ericsson (NASDAQ:ERIC) monthly performance is 1.90%. Ericsson (NASDAQ:ERIC) is expected to post quarterly earnings on 2015-04-23. Investors will be eagerly eyeing the number the company reports compared to the earnings per share that brokers are predicting. Sell-side firms are looking for the company to post EPS of $0.13 for the quarter ending on 2015-03-31.

U.S. Bancorp (NYSE:USB) in last trading activity fell -1.27% to close at $43.53. Company weekly performance is 0.42% while its quarterly performance stands at 2.86%. U.S. Bancorp (NYSE:USB) is -4.72% away from its 52 week high. According to Zacks U.S. Bancorp (NYSE:USB) carries a Rank #3 which shows increase in the predictive power of ESP.

On last trading day NeuroMetrix Inc. (NASDAQ:NURO) fell -1.09% to close at $1.41. Its volatility for the week is 10.03% while volatility for the month is 5.78%. NURO’s sales growth for past 5 years was -26.80% and its EPS growth for past 5 years was 46.60%. NeuroMetrix Inc. (NASDAQ:NURO) monthly performance is -16.07%. A new wearable device called Quell claims to provide drug-free pain relief by utilizing electric pulses to turn down pain signals in the brain, and all with the simple touch of a button. The Quell device, created by NeuroMetrix Inc. (NASDAQ:NURO), consists of two electrodes on a simple black band that wraps around the top of the calf, an area packed full of sensory nerve endings.

Alcatel Lucent SA (ADR) (NYSE:ALU) has institutional ownership stands at 4.70%. In last trading activity company’s stock closed at $4.93. Nokia and Alcatel-Lucent SA (ADR) (NYSE:ALU) announced their intention to combine to create an innovation leader in next generation technology and services for an IP connected world. The two companies have entered into a memorandum of understanding under which Nokia will make an offer for all of the equity securities issued by Alcatel-Lucent, through a public exchange offer in France and in the United States, on the basis of 0.55 of a new Nokia share for every Alcatel-Lucent share.

On last trading day Pfizer Inc. (NYSE:PFE) moved down -0.17% to close at $35.03. Its volatility for the week is 1.49% while volatility for the month is 1.56%. PFE’s sales growth for past 5 years was 0.10% and its EPS growth for past 5 years was 3.10%. Pfizer Inc. (NYSE:PFE) monthly performance is 3.03%. Mylan (NYSE:MYL) announced that it has entered into an agreement with Pfizer Inc. (PFE) to settle patent litigation relating to Mylan’s abbreviated new drug application for its generic version of Pfizer’s Viagra (25 mg, 50 mg, and 100 mg). Viagra, indicated to treat erectile dysfunction, generated U.S. revenues of approximately $1.3 billion for the twelve months ending Dec 31, 2014, as per data provided by IMS Health.


Leave a Reply

Your email address will not be published. Required fields are marked *